Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Silberstein

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal for Immunotherapy of Cancer|May 17, 2022
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cellsSainiteesh Maddineni, John L Silberstein, John B Sunwoo
Current Urology Reports|February 24, 2016
Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerJohn L Silberstein, Maritza N Taylor, Emmanuel S Antonarakis
JCO Precision Oncology|November 25, 2017
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate CancerMark C Markowski, John L Silberstein, James R Eshleman, et al.
The Prostate|January 26, 2018
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancerPedro Isaacsson Velho, John L Silberstein, Mark C Markowski, et al.
Frontiers in Immunology|March 4, 2021
CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell FunctionKartik Bhamidipati, John L Silberstein, Yashaar Chaichian, et al.
European Urology|February 15, 2018
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Scientific Reports|September 17, 2020
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTANishant Mehta, Sainiteesh Maddineni, Ryan L Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and functionJohn L Silberstein, Jasper Du, Kun-Wei Chan, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal for Immunotherapy of Cancer|May 17, 2022
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cellsSainiteesh Maddineni, John L Silberstein, John B Sunwoo
Current Urology Reports|February 24, 2016
Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerJohn L Silberstein, Maritza N Taylor, Emmanuel S Antonarakis
JCO Precision Oncology|November 25, 2017
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate CancerMark C Markowski, John L Silberstein, James R Eshleman, et al.
The Prostate|January 26, 2018
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancerPedro Isaacsson Velho, John L Silberstein, Mark C Markowski, et al.
Frontiers in Immunology|March 4, 2021
CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell FunctionKartik Bhamidipati, John L Silberstein, Yashaar Chaichian, et al.
European Urology|February 15, 2018
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Scientific Reports|September 17, 2020
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTANishant Mehta, Sainiteesh Maddineni, Ryan L Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and functionJohn L Silberstein, Jasper Du, Kun-Wei Chan, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Pageof 2